Synthesis of novel 6-substituted amino-9-(β-d-ribofuranosyl)purine analogs and their bioactivities on human epithelial cancer cells
作者:Meral Tuncbilek、Aslıgul Kucukdumlu、Ebru Bilget Guven、Duygu Altiparmak、Rengul Cetin-Atalay
DOI:10.1016/j.bmcl.2017.12.070
日期:2018.2
New nucleoside derivatives with nitrogen substitution at the C-6 position were prepared and screened initially for their in vitro anticancer bioactivity against human epithelial cancer cells (liver Huh7, colon HCT116, breast MCF7) by the NCI-sulforhodamine B assay. N6-(4-trifluoromethylphenyl)piperazine analog (27) exhibited promising cytotoxic activity. The compound 27 was more cytotoxic (IC50 = 1–4 μM)
制备了在C-6位置具有氮取代的新核苷衍生物,并通过NCI-磺胺丁丹B试验初步筛选了它们对人上皮癌细胞(肝Huh7,结肠HCT116,乳腺MCF7)的体外抗癌生物活性。N 6-(4-三氟甲基苯基)哌嗪类似物(27)表现出有希望的细胞毒性活性。 在Huh7,HCT116和MCF7细胞系上,化合物27比5-FU,氟达拉滨具有更高的细胞毒性(IC 50 = 1-4μM)。最有效的核苷(11,13,16,18,19,21,27,(28)进一步筛选了它们在肝细胞癌细胞系中的细胞毒性。化合物27对Huh7,Mahlavu和FOCUS细胞表现出最高的细胞毒活性(IC 50 分别为1、3和1μM)。分子的理化性质,药物相似性和药物得分曲线表明,它们被认为具有口服生物利用度。结果表明,新型衍生物将是潜在的药物候选物。